[{"id":"4829b067-17e9-4303-a9f1-a51640780137","acronym":"","url":"https://clinicaltrials.gov/study/NCT07211737","created_at":"2025-10-11T01:28:20.312Z","updated_at":"2025-10-11T01:28:20.312Z","phase":"Phase 1","brief_title":"NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma","source_id_and_acronym":"NCT07211737","lead_sponsor":"Baylor College of Medicine","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2043","study_completion_date":" 12/01/2043","last_update_posted":"2025-10-08"},{"id":"25349538-1543-4f27-bdeb-cda4c2e84fbc","acronym":"REALL_CART","url":"https://clinicaltrials.gov/study/NCT06709469","created_at":"2025-02-26T11:15:24.869Z","updated_at":"2025-02-26T11:15:24.869Z","phase":"Phase 1","brief_title":"Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults","source_id_and_acronym":"NCT06709469 - REALL_CART","lead_sponsor":"Instituto de Investigación Hospital Universitario La Paz","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2030","primary_completion_date":" 06/01/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-11-28"},{"id":"7bf35929-12d7-4980-addf-673178a01848","acronym":"CAR4SAR","url":"https://clinicaltrials.gov/study/NCT06087341","created_at":"2023-10-17T15:12:54.468Z","updated_at":"2024-07-02T16:35:09.876Z","phase":"Phase 1","brief_title":"A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma","source_id_and_acronym":"NCT06087341 - CAR4SAR","lead_sponsor":"Antonio Pérez Martínez","biomarkers":" NKG2D • ULBP2","pipe":"","alterations":" ","tags":["NKG2D • ULBP2"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/10/2024","start_date":" 01/10/2024","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-04-12"},{"id":"3cc68517-997b-45c0-9418-e55247f24f07","acronym":"","url":"https://clinicaltrials.gov/study/NCT04414540","created_at":"2024-02-28T17:31:07.888Z","updated_at":"2024-07-02T16:35:17.528Z","phase":"Phase 2","brief_title":"Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients","source_id_and_acronym":"NCT04414540","lead_sponsor":"Trisha Wise-Draper","biomarkers":" IL6 • TNFA • CXCL8 • STAT3 • IL2 • IL10 • IL4 • NKG2D","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • STAT3 • IL2 • IL10 • IL4 • NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/31/2020","start_date":" 08/31/2020","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-02-28"},{"id":"ce910ebc-2111-40c9-8011-63c73b539176","acronym":"","url":"https://clinicaltrials.gov/study/NCT04898543","created_at":"2021-05-24T15:53:54.007Z","updated_at":"2024-07-02T16:35:22.660Z","phase":"Phase 1","brief_title":"QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04898543","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" CD4 • NKG2D","pipe":"","alterations":" ","tags":["CD4 • NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/21/2021","start_date":" 06/21/2021","primary_txt":" Primary completion: 06/21/2024","primary_completion_date":" 06/21/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-23"},{"id":"6d1193f0-2ca7-4f62-ac97-d72d00f1ac1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05734898","created_at":"2023-02-21T16:01:41.195Z","updated_at":"2024-07-02T16:35:54.158Z","phase":"","brief_title":"NKG2D CAR-NK \u0026 r/rAML","source_id_and_acronym":"NCT05734898","lead_sponsor":"Zhejiang University","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NKG2D CAR-NK cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-03-03"},{"id":"c89e4f6e-89dc-462f-b9c4-dad107cbf4e2","acronym":"ANGELICA","url":"https://clinicaltrials.gov/study/NCT05302037","created_at":"2022-03-31T18:52:43.718Z","updated_at":"2024-07-02T16:36:14.486Z","phase":"Phase 1","brief_title":"Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers","source_id_and_acronym":"NCT05302037 - ANGELICA","lead_sponsor":"CytoMed Therapeutics Pte Ltd","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTM-N2D"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-03-31"},{"id":"c8dca8c7-a482-4d7b-823f-95465ef1e767","acronym":"","url":"https://clinicaltrials.gov/study/NCT05131763","created_at":"2021-11-23T13:53:39.639Z","updated_at":"2024-07-02T16:36:20.316Z","phase":"Phase 1","brief_title":"NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors","source_id_and_acronym":"NCT05131763","lead_sponsor":"Fudan University","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KD-025 CAR T-cells"],"overall_status":"Recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2021-11-23"},{"id":"371d58a2-25f1-4a65-ae93-d66ba3aa87c2","acronym":"DEPLETHINK","url":"https://clinicaltrials.gov/study/NCT03466320","created_at":"2021-01-18T17:05:05.194Z","updated_at":"2024-07-02T16:36:30.744Z","phase":"Phase 1/2","brief_title":"DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2","source_id_and_acronym":"NCT03466320 - DEPLETHINK","lead_sponsor":"Celyad Oncology SA","biomarkers":" TP53 • NKG2D","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CYAD-01 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 09/18/2018","start_date":" 09/18/2018","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2021-05-04"},{"id":"a5b151fc-9227-45c1-95c7-a185934aa520","acronym":"","url":"https://clinicaltrials.gov/study/NCT04658004","created_at":"2021-01-19T20:41:58.819Z","updated_at":"2024-07-02T16:36:37.733Z","phase":"Phase 1","brief_title":"NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04658004","lead_sponsor":"Zhejiang University","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NKG2D CAR T-cells"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/15/2021","start_date":" 01/15/2021","primary_txt":" Primary completion: 01/15/2024","primary_completion_date":" 01/15/2024","study_txt":" Completion: 01/15/2027","study_completion_date":" 01/15/2027","last_update_posted":"2020-12-08"},{"id":"c9395786-642c-48a0-963b-5b5caa304711","acronym":"","url":"https://clinicaltrials.gov/study/NCT01392989","created_at":"2021-01-18T05:43:11.496Z","updated_at":"2024-07-02T16:36:59.855Z","phase":"Phase 2","brief_title":"Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders","source_id_and_acronym":"NCT01392989","lead_sponsor":"Everett Meyer","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 06/07/2016","primary_completion_date":" 06/07/2016","study_txt":" Completion: 03/19/2017","study_completion_date":" 03/19/2017","last_update_posted":"2019-05-07"},{"id":"274eb1bc-b7e2-4f3a-8079-17219e08b1f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00439465","created_at":"2021-01-18T01:33:08.291Z","updated_at":"2024-07-02T16:37:01.293Z","phase":"Phase 2","brief_title":"Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma","source_id_and_acronym":"NCT00439465","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" CD8 • IL2 • NCAM1 • CSF2 • NKG2D","pipe":"","alterations":" ","tags":["CD8 • IL2 • NCAM1 • CSF2 • NKG2D"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 01/01/2007","start_date":" 01/01/2007","primary_txt":" Primary completion: 10/15/2012","primary_completion_date":" 10/15/2012","study_txt":" Completion: 11/30/2012","study_completion_date":" 11/30/2012","last_update_posted":"2019-03-26"}]